KYMERA THERAPEUTICS

Serial Number 88203331
606

Registration Progress

Application Filed
Nov 22, 2018
Under Examination
Jan 12, 2021
Approved for Publication
Oct 8, 2019
Published for Opposition
Oct 8, 2019
Registered

Trademark Image

KYMERA THERAPEUTICS

Basic Information

Serial Number
88203331
Filing Date
November 22, 2018
Published for Opposition
October 8, 2019
Abandonment Date
August 14, 2023
Drawing Code
3000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Aug 14, 2023
Classes
005 042

Rights Holder

Kymera Therapeutics, Inc.

03
Address
200 Arsenal Yards Blvd., Suite 230
Watertown, MA 02472

Ownership History

Kymera Therapeutics, Inc.

Original Applicant
03
Cambridge, MA

Kymera Therapeutics, Inc.

Owner at Publication
03
Watertown, MA

Legal Representation

Attorney
GLENN A GUNDERSEN

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

39 events
Date Code Type Description
Aug 14, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Aug 14, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 13, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 11, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 11, 2023 EXT4 S SOU EXTENSION 4 FILED
Jan 11, 2023 EX4G S SOU EXTENSION 4 GRANTED
Jul 14, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 12, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 12, 2022 EXT3 S SOU EXTENSION 3 FILED
Jul 12, 2022 EX3G S SOU EXTENSION 3 GRANTED
Jan 13, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 11, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 11, 2022 EXT2 S SOU EXTENSION 2 FILED
Jan 11, 2022 EX2G S SOU EXTENSION 2 GRANTED
Jul 14, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 12, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 12, 2021 EXT1 S SOU EXTENSION 1 FILED
Jul 12, 2021 EX1G S SOU EXTENSION 1 GRANTED
Jan 12, 2021 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 3, 2020 OP.T T OPPOSITION TERMINATED NO. 999999
Dec 3, 2020 TMBN T TTAB RELEASE CASE TO TRADEMARKS
Nov 2, 2020 OP.D T OPPOSITION DISMISSED NO. 999999
Nov 14, 2019 OP.I T OPPOSITION INSTITUTED NO. 999999
Nov 7, 2019 OPPF T OPPOSITION PAPERS RECEIVED AT TTAB
Oct 8, 2019 PUBO A PUBLISHED FOR OPPOSITION
Oct 8, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 18, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 5, 2019 ALIE A ASSIGNED TO LIE
Sep 3, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 24, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 23, 2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 23, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 26, 2019 CNRT R NON-FINAL ACTION WRITTEN
Feb 26, 2019 GNRT F NON-FINAL ACTION E-MAILED
Feb 26, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 25, 2019 DOCK D ASSIGNED TO EXAMINER
Dec 13, 2018 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Dec 12, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 26, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
House mark for pharmaceutical and medical preparations for the treatment of oncology, autoimmune, immune-oncology and other related diseases; House mark for pharmaceutical and medical therapeutics for the treatment of oncology, autoimmune, immune-oncology and other related diseases; House mark for diagnostic reagents for the treatment of oncology, autoimmune, immune-oncology and other related diseases
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Research and development of therapeutic drugs for the treatment of oncology, autoimmune, immune-oncology and other related diseases; Research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; Development of pharmaceutical preparations and medicines; Drug development and discovery; Medical research for development of therapeutic modalities for treatment of diseases; Assays and reagents for use in scientific and biomedical research; Clinical studies; Preclinical and clinical development of therapeutic products
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of several geometric designs that form the basic elements of an animal face, to the right of the design appears the wording "KYMERA THERAPEUTICS" in capital stylized letters.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"